Belletti Alessandro, D'Andria Ursoleo Jacopo, Piazza Enrica, Mongardini Edoardo, Paternoster Gianluca, Guarracino Fabio, Palumbo Diego, Monti Giacomo, Marmiere Marilena, Calabrò Maria Grazia, Landoni Giovanni, Zangrillo Alberto
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Artif Organs. 2025 Feb;49(2):183-195. doi: 10.1111/aor.14864. Epub 2024 Sep 21.
Barotrauma is a frequent complication in patients with severe respiratory failure and is associated with poor outcomes. Extracorporeal membrane oxygenation (ECMO) implantation allows to introduce lung-protective ventilation strategies that limit barotrauma development or progression, but available data are scarce. We performed a scoping review to summarize current knowledge on this therapeutic approach.
We systematically searched PubMed/MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies investigating ECMO as a strategy to prevent/limit barotrauma progression in patients with respiratory failure. Pediatric studies, studies on perioperative implantation of ECMO, and studies not reporting original data were excluded. The primary outcome was the rate of barotrauma development/progression.
We identified 21 manuscripts presenting data on a total of 45 ECMO patients. All patients underwent veno-venous ECMO. Of these, 21 (46.7%) received ECMO before invasive mechanical ventilation. In most cases, ECMO implantation allowed to modify the respiratory support strategy (e.g., introduction of ultraprotective/low pressure ventilation in 12 patients, extubation while on ECMO in one case, and avoidance of invasive ventilation in 15 cases). Barotrauma development/progression occurred in <10% of patients. Overall mortality was 8/45 (17.8%).
ECMO implantation to prevent barotrauma development/progression is a feasible strategy and may be a promising support option.
气压伤是严重呼吸衰竭患者常见的并发症,且与不良预后相关。体外膜肺氧合(ECMO)植入可采用肺保护性通气策略,限制气压伤的发生或进展,但现有数据较少。我们进行了一项范围综述,以总结关于这种治疗方法的现有知识。
我们系统检索了PubMed/MEDLINE、EMBASE和Cochrane对照试验中央注册库,以查找将ECMO作为预防/限制呼吸衰竭患者气压伤进展策略的研究。排除儿科研究、ECMO围手术期植入的研究以及未报告原始数据的研究。主要结局是气压伤发生/进展的发生率。
我们确定了21篇手稿,共提供了45例ECMO患者的数据。所有患者均接受了静脉-静脉ECMO。其中,21例(46.7%)在有创机械通气前接受了ECMO。在大多数情况下,ECMO植入允许改变呼吸支持策略(例如,12例患者采用超保护性/低压通气,1例在ECMO支持下拔管,15例避免有创通气)。气压伤发生/进展的患者不到10%。总体死亡率为8/45(17.8%)。
植入ECMO以预防气压伤发生/进展是一种可行的策略,可能是一种有前景的支持选择。